diabetes management

Glucotrack submits IDE application for FDA clinical trial of implantable continuous glucose monitoring technology, marking major regulatory milestone for diabetes care innovation.

DexCom beats Q1 earnings with $1.2B revenue, boasts 20 Buy ratings. New products and margin expansion drive 40% upside potential.

DarioHealth reports Q1 2026 earnings on May 13, 2026, with CEO, President, and CFO discussing financial results and strategic initiatives via conference call.

Senseonics raises $80M through common stock and pre-funded warrant offering to fund Eversense 365 launch and pipeline development, closing May 4, 2026.

Middle East and Africa CGM market projected to reach USD 855.30 million by 2034 from USD 320.44 million in 2025, growing at 11.53% CAGR.

Senseonics launches Eversense 365 implantable glucose monitor in Europe with one-year lifespan. Q4 revenue surged 72% year-over-year to $14.3 million.

DexCom benefits from GLP-1 weight-loss drug adoption regardless of pharmaceutical winner, leveraging competitive moats in CGM technology and ecosystem integration.

Glucotrack narrowed net losses to $19.4M in 2025 while advancing implantable glucose monitor toward FDA trials in H2 2026.

Senseonics reports real-world data from 5,059 Eversense 365 CGM users showing 93.8% wear time and strong glucose control metrics over one year.

Global IV infusion pump market projected to grow from $6.72B in 2025 to $14.02B by 2035 at 7.6% CAGR, driven by aging populations and smart pump technology.

Survey of 4,326 diabetics across 22 countries shows 80% demand predictive glucose forecasting tools, revealing unmet market need beyond current continuous glucose monitoring.

Trinity Biotech received a Nasdaq non-compliance notice for failing to maintain minimum share value requirements. The company has 180 days to restore compliance or face delisting.